Hexokinase 2在卵巢癌中的表达及临床病理意义

The clinical pathological significance of Hexokinase 2 expression in ovarian cancer

目的:探讨卵巢癌中Hexokinase 2(HK-2)表达的临床病理意义。方法:免疫组化检测56例卵巢癌组织及10例癌旁组织中HK-2的表达情况,并对临床病理数据进行分析。MTT法和流式细胞分析分别检测siRNA沉默HK-2蛋白对卵巢癌Skov3细胞增殖及凋亡的影响。Western Blot检测凋亡蛋白Caspase-3的表达。结果:10例癌旁组织中均未见HK-2阳性表达,56卵巢癌中HK-2的阳性表达率为53.6%(30/56)。HK-2高表达与卵巢癌患者肿瘤分期较高(P=0.018)、肿瘤淋巴结转移密切相关(P=0.035),但与患者年龄(P=0.410)、肿瘤组织学分级(P=0.108)、肿瘤组织学类型(P=0.122)、复发(P=0.160)无显著相关性。siRNA沉默HK-2蛋白抑制卵巢癌Skov3细胞增殖,促进凋亡。Western Blot检测蛋白提示siRNA沉默HK-2蛋白促进了调亡蛋白Caspase-3的表达。结论:卵巢癌中存在HK-2高表达,HK-2在卵巢上皮癌可能发挥了促进肿瘤发生和进展的重要作用,可能是一种新的上皮卵巢癌治疗靶点。

Objective： To explore the clinical pathological significance of Hexokinase 2（ HK- 2） expression in ovarian cancer. Methods： Immunohistochemistry was used to detect HK- 2 expression in 68 cases of ovarian cancer tissue. Results： In 56 ovarian cancer patients HK- 2 expression positive rate was 53. 6%（ 30 /56）. High HK- 2 expression was reltated with ovarian tumor staging（ P = 0. 018）,lymph node metastasis（ P = 0. 035）,but not related with age,differentiation,histology,and ascites. Conclusion： High HK- 2 expression exist in ovarian cancer,MTDH may play an important role in tumor growth and development. Ttargeting HK- 2 treatment may have important value for patients.